Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.025 | 0.7 |
mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.7 |
mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.7 |